Clinical Trial Update: Dose Tapering Study of Adalimumab in Psoriasis [Phase 4]

View source ↗

Summary

A Phase 4 dose-tapering trial of adalimumab for psoriasis has been terminated. The study was sponsored by University Hospital Ghent.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: University Hospital, Ghent | Conditions: Psoriasis Vulgaris | Phase 4 | Status: TERMINATED